Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia [Phase 3]

View source ↗

Summary

Phase 3 trial for SAGE-217 in adults with comorbid Major Depressive Disorder and Insomnia was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia
• Major Depressive Disorder

Drugs mentioned

• SAGE-217 (zuranolone)

Snippet

Sponsor: Biogen | Conditions: Major Depressive Disorder, Insomnia | Phase 3 | Status: TERMINATED | Results posted: 2022-10-20